Catalog No.: PC-38499Not For Human Use, Lab Use Only.
Cenicriviroc (TAK-652, TBR-652) is a potent, selective, orally active, dual CCR2/CCR5 antagonist with IC50 of 5.9/0.29 nM, inhibits both HIV-1 and HIV-2 and prevents viral cellular entry.
Cenicriviroc (TAK-652, TBR-652) is a potent, selective, orally active, dual CCR2/CCR5 antagonist with IC50 of 5.9/0.29 nM, inhibits both HIV-1 and HIV-2 and prevents viral cellular entry.
Cenicriviroc (TAK-652, TBR-652) exhibits effective EC50 of 0.03, 0.33, 0.45 and 0.98 nM against 4 R5 HIV-2 clinical isolates.
Cenicriviroc (≥20 mg/kg/day) significantly reduces monocyte/macrophage recruitment in vivo.
Cenicriviroc (TAK-652, TBR-652) shows antifibrotic effects, with significant reductions in collagen deposition, and collagen type 1 protein and mRNA expression across animal models of fibrosis.
